NDAINJECTIONINJECTABLEPriority Review
Approved
Jun 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORINASE DIAGNOSTIC (tolbutamide sodium) is an injectable diagnostic agent approved in 1961 as a first-generation sulfonylurea derivative used for glucose tolerance testing. It is administered intravenously to assess pancreatic beta-cell insulin secretion capacity in patients suspected of having diabetes or hypoglycemia. The drug works by stimulating insulin release from functioning beta cells, allowing clinicians to differentiate between insulin-secreting and non-secreting pancreatic disorders.
LOE Approaching
As a legacy diagnostic agent approaching LOE with no active patents and minimal linked job opportunities, the brand team is likely minimal and focused on maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job opportunities and a product in LOE-approaching status, career prospects on ORINASE DIAGNOSTIC are severely limited. Roles available would be narrow, maintenance-focused positions in regulatory or medical affairs with minimal growth trajectory.
Regulatory Affairs SpecialistProduct Manager (Diagnostics)
Worked on ORINASE DIAGNOSTIC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.